A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Facial adenocarcinoma treated with intra-arterial chemotherapy

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

Efficacy of the long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet laser (LPND) (rejuvenation mode) in the treatment of papulopustular rosacea (PPR):

A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: A randomized, physician-blinded,

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Blaschkoid pityriasis rosea

Baldness reversed by chemotherapy

Efficacy of simvastatin in plaque psoriasis: A pilot study

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Combined acitretin and Candida antigen versus either agent alone in the treatment of recalcitrant warts Ahmad Nofal, MD, Fathia Khattab, MD, Eman Nofal,

Efficacy of topical application of eosin for ulcerated hemangiomas

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Infectious rash after riding elephants

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial Lauren Okon, MD, Misha Rosenbach, MD, Michael.

Lip edema Journal of the American Academy of Dermatology

Adult-onset multiple myofibromas

Stephanie D. Gan, MD, Sarah H

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Jeffrey Freed, MD, Jennifer Smith, MD

Spontaneous involution of congenital melanocytic nevi of the scalp

Volume 4, Issue 6, Pages (July 2018)

Hugh Gloster, MD, Chesahna Kindred, MBA

Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of simple onycholysis: An open-label study Jung-Min Park, MD,

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: A comparison of a skin.

Descriptive survival study of nail melanoma patients treated with functional surgery versus distal amputation Suelen Montagner, MD, Francisco Aparecido.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

A grayscale photograph with high dynamic range taken under a Wood's lamp for better recognition of vitiligo lesions Jung Min Bae, MD, PhD, Tae Young.

Efficacy and safety of oxymetazoline cream 1

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

A randomized, controlled, prospective clinical study comparing a novel skin closure device to conventional suturing Hadeel Mitwalli, MD, Christopher.

Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Presentation transcript:

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles Rhoda S. Narins, MD, Leslie Baumann, MD, Fredric S. Brandt, MD, Steven Fagien, MD, Scott Glazer, MD, Nicholas J. Lowe, MD, FRCP, Gary D. Monheit, MD, Marta I. Rendon, MD, Rod J. Rohrich, MD, Wm. Philip Werschler, MD Journal of the American Academy of Dermatology Volume 62, Issue 3, Pages 448-462 (March 2010) DOI: 10.1016/j.jaad.2009.07.040 Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Subject disposition diagram. Journal of the American Academy of Dermatology 2010 62, 448-462DOI: (10.1016/j.jaad.2009.07.040) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Improvement in Wrinkle Assessment Scale (WAS) score, as shown by mean (standard error [SE]) change from baseline by visit. Scale of figure has been reversed to show positive improvement, correlating with decreasing WAS values from baseline. Week 3 (W3) is first follow-up time point after final treatment session. Subjects received between one and 4 treatments every 3 weeks until optimum correction. M, Month. ∗P < .001 vs baseline; †P < .001 vs human collagen; ‡only subjects treated with injectable poly-L-lactic acid (PLLA) (n = 106) were included in long-term surveillance phase. Journal of the American Academy of Dermatology 2010 62, 448-462DOI: (10.1016/j.jaad.2009.07.040) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Left and right nasolabial folds of subjects before (left) and 13 and 25 months after (middle and right, respectively) treatment with injectable poly-L-lactic acid: mild (36-year-old woman) (A), moderate (44-year-old woman) (B), and severe (57-year-old woman) (C). Journal of the American Academy of Dermatology 2010 62, 448-462DOI: (10.1016/j.jaad.2009.07.040) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Left and right nasolabial folds of subjects before (left) and 13 and 25 months after (middle and right, respectively) treatment with injectable poly-L-lactic acid: mild (36-year-old woman) (A), moderate (44-year-old woman) (B), and severe (57-year-old woman) (C). Journal of the American Academy of Dermatology 2010 62, 448-462DOI: (10.1016/j.jaad.2009.07.040) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions